These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10930162)

  • 1. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.
    Moyle GJ; Wilkins E; Leen C; Cheesbrough A; Reynolds B; Gazzard BG
    AIDS; 2000 Jul; 14(10):1453-4. PubMed ID: 10930162
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
    Wasmuth JC; Herhaus C; Römer K; Salzberger B; Kaiser R; Schliefer K; Voigt E; Rockstroh JK
    AIDS; 2002 May; 16(7):1077-8. PubMed ID: 11953478
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
    N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacement of protease inhibitors by nevirapine or efavirenz in simplification and rescue interventions: which works better?
    Barreiro P; Camino N; De Julián R; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(4):244-7. PubMed ID: 12916009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?
    Carr A
    Lancet; 2004 Apr; 363(9417):1248-50. PubMed ID: 15094265
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
    Bommenel T; Launay O; Meynard JL; Gilquin J; Katlama C; Lascaux AS; Mahamat A; Martinez V; Pradier C; Rouveix E; Simon A; Costagliola D; Abgrall S;
    J Antimicrob Chemother; 2011 Aug; 66(8):1869-77. PubMed ID: 21636583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
    Fisac C; Fumero E; Crespo M; Roson B; Ferrer E; Virgili N; Ribera E; Gatell JM; Podzamczer D
    AIDS; 2005 Jun; 19(9):917-25. PubMed ID: 15905672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What's new and what's next.
    Fakuda D
    Posit Dir News; 1998 Jan; 10(1):25-9. PubMed ID: 11365053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.
    Manfredi R; Chiodo F
    Int J Antimicrob Agents; 2001 Jun; 17(6):511-6. PubMed ID: 11397623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the combination of efavirenz and abacavir in HIV-infected patients failing antiretroviral therapy.
    Tenorio AR; Irlanda IE; Narkiewicz E; Smith KY; Kessler HA; Sha BE
    AIDS; 2000 Jul; 14(10):1470-1. PubMed ID: 10930173
    [No Abstract]   [Full Text] [Related]  

  • 14. Salvage therapy studies.
    Proj Inf Perspect; 1998 Sep; (25):7. PubMed ID: 11365850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four new antiretroviral medications will soon offer more options to HIV patients.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(4):1-3. PubMed ID: 11365545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors.
    Arranz-Caso JA; Gorgolas M; Estrada V; García-Diaz JD
    HIV Med; 2004 Mar; 5(2):128-9. PubMed ID: 15012654
    [No Abstract]   [Full Text] [Related]  

  • 19. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.